Full Text:   <1563>

CLC number: R54

On-line Access: 

Received: 2008-11-02

Revision Accepted: 2009-03-03

Crosschecked: 2009-06-08

Cited: 0

Clicked: 4242

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2009 Vol.10 No.7 P.528~535

http://doi.org/10.1631/jzus.B0820351


Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest


Author(s):  Shao-xiang WENG, Mei-hua SUI, Shan CHEN, Jian-an WANG, Geng XU, Ji MA, Jiang SHAN, Lu FANG

Affiliation(s):  Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   wengshaox@sina.com

Key Words:  Parthenolide, Vascular smooth muscle cell (VSMC), Cell proliferation, I&kappa, B&alpha


Shao-xiang WENG, Mei-hua SUI, Shan CHEN, Jian-an WANG, Geng XU, Ji MA, Jiang SHAN, Lu FANG. Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest[J]. Journal of Zhejiang University Science B, 2009, 10(7): 528~535.

@article{title="Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest",
author="Shao-xiang WENG, Mei-hua SUI, Shan CHEN, Jian-an WANG, Geng XU, Ji MA, Jiang SHAN, Lu FANG",
journal="Journal of Zhejiang University Science B",
volume="10",
number="7",
pages="528~535",
year="2009",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B0820351"
}

%0 Journal Article
%T Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest
%A Shao-xiang WENG
%A Mei-hua SUI
%A Shan CHEN
%A Jian-an WANG
%A Geng XU
%A Ji MA
%A Jiang SHAN
%A Lu FANG
%J Journal of Zhejiang University SCIENCE B
%V 10
%N 7
%P 528~535
%@ 1673-1581
%D 2009
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B0820351

TY - JOUR
T1 - Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest
A1 - Shao-xiang WENG
A1 - Mei-hua SUI
A1 - Shan CHEN
A1 - Jian-an WANG
A1 - Geng XU
A1 - Ji MA
A1 - Jiang SHAN
A1 - Lu FANG
J0 - Journal of Zhejiang University Science B
VL - 10
IS - 7
SP - 528
EP - 535
%@ 1673-1581
Y1 - 2009
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B0820351


Abstract: 
Objective: This study is to determine the effect of the natural product parthenolide, a sesquiterpene lactone isolated from extracts of the herb Tanacetum parthenium, on the proliferation of vascular smooth muscle cells (VSMCs). Methods: Rat aortic VSMCs were isolated and cultured in vitro, and treated with different concentrations of parthenolide (10, 20 and 30 μmol/L). [3H]thymidine incorporation was used as an index of cell proliferation. Cell cycle progression and distribution were determined by flow cytometric analysis. Furthermore, the expression of several regulatory proteins relevant to VSMC proliferation including i&kappa;b&alpha;, cyclooxygenase-2 (Cox-2), p21, and p27 was examined to investigate the potential molecular mechanism. Results: Treatment with parthenolide significantly decreased the [3H]thymidine incorporation into DNA by 30%~56% relative to control values in a dose-dependent manner (P<0.05). Addition of parthenolide also increased cell population at G0/G1 phase by 19.2%~65.7% (P<0.05) and decreased cell population at S phase by 50.7%~84.8% (P<0.05), which is consistent with its stimulatory effects on p21 and p27. In addition, parthenolide also increased i&kappa;b&alpha; expression and reduced Cox-2 expression in a time-dependent manner. Conclusion: Our results show that parthenolide significantly inhibits the VSMC proliferation by inducing G0/G1 cell cycle arrest. i&kappa;b&alpha; and Cox-2 are likely involved in such inhibitory effect of parthenolide on VSMC proliferation. These findings warrant further investigation on potential therapeutic implications of parthenolide on VSMC proliferation in vivo.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Baeuerle, P.A., Henkel, T., 1994. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol., 12(1):141-179.

[2] Bishop-Bailey, D., Hla, T., Mitchell, J.A., 1999. Cyclo-oxygenase-2 in vascular smooth muscle. Int. J. Mol. Med., 3(1):41-48.

[3] Brown, K., Park, S., Kanno, T., Franzoso, G., Siebenlist, U., 1993. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. USA, 90(6):2532-2536.

[4] Chen, F., Castranova, V., Shi, X., Demers, L.M., 1999. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem., 45(1):7-17.

[5] Collins, T., Cybulsky, M.I., 2001. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 107(3):255-264.

[6] Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., van de Putte, L.B., Lipsky, P.E., 1998. Cyclooxygenase in biology and disease. FASEB J., 12(12):1063-1073.

[7] Gomez-Hernandez, A., Martin-Ventura, J.L., Sanchez-Galan, E., Vidal, C., Ortego, M., Blanco-Colio, L.M., Ortegan, L., Tunon, J., Egido, J., 2006. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis, 187(1):139-149.

[8] Groenewegen, W.A., Heptinstall, S., 1990. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J. Pharm. Pharmacol., 42(8):553-557.

[9] Hedin, U., Roy, J., Tran, P.K., 2004. Control of smooth muscle cell proliferation in vascular disease. Curr. Opin. Lipidol., 15(5):559-565.

[10] Hehner, S.P., Heinrich, M., Bork, P.M., Vogt, M., Ratter, F., Lehmann, V., Schulze-Osthoff, K., Droge, W., Schmitz, M.L., 1998. Sesquiterpene lactones specifically inhibit activation of NF-kappaB by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem., 273(3):1288-1297.

[11] Hehner, S.P., Hofmann, T.G., Droge, W., Schmitz, M.L., 1999. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol., 163(10):5617-5623.

[12] Heinrich, M., Robles, M., West, J.E., Ortiz de Montellano, B.R., Rodriguez, E., 1998. Ethnopharmacology of Mexican asteraceae (Compositae). Annu. Rev. Pharmacol. Toxicol., 38(1):539-565.

[13] Hengst, L., Reed, S.I., 1998. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol., 227:25-41.

[14] Knight, D.W., 1995. Feverfew: chemistry and biological activity. Nat. Prod. Rep., 12(3):271-276.

[15] López-Franco, O., Hernández-Vargas, P., Ortiz-Muñoz, G., Sanjuán, G., Suzuki, Y., Ortega, L., Blanco, J., Egido, J., Gómez-Guerrero, C., 2006. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 26(8):1864-1870.

[16] Maddika, S., Ande, S.R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K.D., Wiechec, E., Los, M., 2007. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug. Resist. Update, 10(1):13-29.

[17] Marnett, L.J., Rowlinson, S.W., Goodwin, D.C., Kalgutkar, A.S., Lanzo, C.A., 1999. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem., 274(33):22903-22906.

[18] Moon, S.K., Cha, B.Y., Kim, C.H., 2004. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J. Cell Physiol., 198(3):417-427.

[19] Nilsson, J., Ksiazek, T., Thyberg, J., 1983. Effects of colchicine on DNA synthesis, endocytosis and fine structure of cultivated arterial smooth muscle cells. Exp. Cell. Res., 143(2):367-375.

[20] Oka, D., Nishimura, K., Shiba, M., Nakai, Y., Arai, Y., Nakayama, M., Takayama, H., Inoue, H., Okuyama, A., Nonomura, N., 2007. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int. J. Cancer, 120(12):2576-2581.

[21] Pang, L., Holland, E., Knox, A.J., 1998. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline. Br. J. Pharmacol., 125(6):1320-1328.

[22] Parada-Turska, J., Paduch, R., Majdan, M., Kandefer-Szerszen, M., Rzeski, W., 2007. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol. Rep., 59(2):233-237.

[23] Rivard, A., Andres, V., 2000. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol., 15(2):557-571.

[24] Ross, J.J., Arnason, J.T., Birnboim, H.C., 1999. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med., 65(2):126-129.

[25] Shanmugam, R., Jayaprakasan, V., Gokmen-Polar, Y., Kelich, S., Miller, K.D., Yipschneider, M., Cheng, L., Bhat-Nakshatri, P., Sledge, G.W.Jr., Nakshatri, H., et al., 2006. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 66(14): 1498-1511.

[26] Sheehan, M., Wong, H.R., Hake, P.W., Malhotra, V., O'Connor, M., Zingarelli, B., 2002. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol. Pharmacol., 61(5):953-963.

[27] Smolinski, A.T., Pestka, J.J., 2005. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J. Inflamm. (Lond)., 2(1):6.

[28] Spyridopoulos, I., Andres, V., 1998. Control of vascular smooth muscle and endothelial cell proliferation and its implication in cardiovascular disease. Front Biosci., 3(1):d269-d287.

[29] Thyberg, J., Palmberg, L., Nilsson, J., Ksiazek, T., Sjolund, M., 1983. Phenotype modulation in primary cultures of arterial smooth muscle cells. On the role of platelet-derived growth factor. Differentiation, 25(2):156-167.

[30] Tzeng, H.P., Yang, R.S., Ueng, T.H., Liu, S.H., 2007. Upregulation of cyclooxygenase-2 by motorcycle exhaust particulate-induced reactive oxygen species enhances rat vascular smooth muscle cell proliferation. Chem. Res. Toxicol., 20(8):1170-1176.

[31] Weissberg, P.L., Grainger, D.J., Shanahan, C.M., Metcalfe, J.C., 1993. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc. Res., 27(7):1191-1198.

[32] Wong, H.R., Menendez, I.Y., 1999. Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun., 262(2):375-380.

[33] Young, W., Mahboubi, K., Haider, A., Li, I., Ferreri, N.R., 2000. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ. Res., 86(8):906-914.

[34] Zingarelli, B., Hake, P.W., Denenberg, A., Wong, H.R., 2002. Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock, 17(2):127-134.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE